Breaking News

Smithers Avanza Expands Bioanalytical Services Division

March 9, 2016

Adds senior scientific and support personnel and new liquid handling robotics instrumentation

Smithers Avanza’s Bioanalytical Services Division has completed an expansion of its bioanalytical lab that will accommodate 33% percent more staff to support client needs during the development of large molecule biologic therapies.
 
“Rising demand for testing from our clients, which include some of the world’s largest biopharmaceutical companies, has resulted in the company more than doubling our scientific and support staff year over year,” said Ira DuBey, executive vice president, Bioanalytical Services Division, Smithers Avanza. “Expanding our lab space helps us create capacity so that we can continue to support our clients with the highest level of service.”
 
The company has added several new staff members, including senior scientific and support personnel for client development of large molecule biologics including immuno-oncology drugs and combination therapies. Additionally, the company acquired new liquid handling robotics instrumentation and another Singulex instrument to support testing of high sensitivity biomarker and pharmacokinetic assays.
blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Why True CDMO Service Requires Flexibility, Responsiveness and Innovation

    James E. Gregory, UPM Pharmaceuticals||October 7, 2015
    Pharmaceutical and biopharmaceutical companies large and small are increasingly relying on third-party providers for support at all stages of drug development. To realize efficiencies, they are at the same time reducing the number of suppliers to a preferred few with whom they can form strategic partnerships.

  • A Case for One Assay Analysis of PK and Immunogenicity in Biosimilar Research

    A Case for One Assay Analysis of PK and Immunogenicity in Biosimilar Research

    Stephanie Mowery, Sherri Rinker, Franklin Spriggs and Bo Kowalcyk , AIT Bioscience||June 2, 2015
    Moving forward clinical studies will have to include a comparative assessment of pharmacokinetics and immunogenicity to the original reference biologic drug